Galectin Therapeutics | GALT - Operating Expenses

Stock Price
3.02
Daily Change
0.05 1.68%
Monthly
-3.21%
Yearly
106.85%
Q1 Forecast
2.88

Galectin Therapeutics reported $11.29M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Galectin Therapeutics USD 11.29M 1.64M Jun/2024
Gilead Sciences USD 4.96B 707M Dec/2025
Immunic USD 25.73M 2.91M Sep/2024
Incyte USD 1.12B 3.53B Dec/2025
Merck USD 10.16B 558M Dec/2025